Get the Stockscreener App
1.31
2.97%
-0.0401
Phio Pharmaceuticals Corp stock is traded at $1.31, with a volume of 278.10K.
It is down -2.97% in the last 24 hours and down -17.09% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$1.3501
Open:
$1.37
24h Volume:
278.10K
Relative Volume:
0.10
Market Cap:
$14.10M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.1606
EPS:
-8.156
Net Cash Flow:
$-11.09M
1W Performance:
+3.97%
1M Performance:
-17.09%
6M Performance:
-46.75%
1Y Performance:
-51.66%
1-Day Range:
$1.31
$1.4263
1-Week Range:
$1.19
$1.4263
52-Week Range:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.31 | 14.53M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
EBIT per share of Phio Pharmaceuticals Corp. – BER:44R1 - TradingView
Will Phio Pharmaceuticals Corp. (44R1) stock beat revenue estimatesMarket Performance Summary & Risk Managed Trade Strategies - Newser
How Phio Pharmaceuticals Corp. (44R1) stock reacts to fiscal policiesJuly 2025 Update & AI Optimized Trading Strategy Guides - Newser
How Phio Pharmaceuticals Corp. (44R1) stock reacts to new regulationsJuly 2025 Selloffs & High Yield Equity Trading Tips - Newser
What technical patterns form on Phio Pharmaceuticals Corp. (44R1) stock chartsJuly 2025 Selloffs & High Yield Equity Trading Tips - Newser
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Phio Pharmaceuticals Corp. (44R1) stock rise with strong economyWeekly Trend Summary & Weekly High Return Stock Opportunities - Newser
Phio Pharma (PHIO) Stock Analysis Report | Financials & Insights - Benzinga
How Phio Pharmaceuticals Corp. (44R1) stock compares with market leadersPortfolio Update Summary & Reliable Entry Point Trade Alerts - Newser
What insider trading reveals about Phio Pharmaceuticals Corp. stockProfit Target & Verified Swing Trading Watchlists - Newser
Can Phio Pharmaceuticals Corp. stock continue upward trendMarket Sentiment Report & Real-Time Volume Analysis - Newser
Why retail investors pile into Phio Pharmaceuticals Corp. stockLayoff News & Low Drawdown Trading Strategies - BỘ NỘI VỤ
MSN Money - MSN
How Phio Pharmaceuticals Corp. stock responds to policy changesMarket Risk Report & Fast Gain Swing Alerts - moha.gov.vn
TARC Limited Earnings Review What Investors Need to KnowMid Cap Growth Trends & Free Risk Assessment and Control - earlytimes.in
Phio Pharmaceuticals Completes Enrollment for PH-762 Trial - TipRanks
Phio Pharmaceuticals Completes Enrollment in Phase 1b Trial of PH-762 - TradingView
Phio Pharmaceuticals Corp. Announces Completion of Enrollment in Phase 1B Clinical Trial of Intasyl Sirna Lead Compound Ph-762 - marketscreener.com
Phio completes enrollment in Phase 1b trial of skin cancer therapy - Investing.com Australia
Phio completes enrollment in Phase 1b trial of skin cancer therapy By Investing.com - Investing.com South Africa
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 - Newsfile
Phio Pharmaceuticals (NASDAQ: PHIO) Reports PH-762 Data With 6 Complete Responses - Stock Titan
[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity - Stock Titan
It is Poised to be a Bull Market for Phio Pharmaceuticals Corp (PHIO) - Setenews
What is HC Wainwright’s Forecast for PHIO FY2025 Earnings? - Defense World
How higher bond yields impact Phio Pharmaceuticals Corp. (44R1) stockJuly 2025 Closing Moves & Smart Swing Trading Alerts - newser.com
Developing predictive dashboards with Phio Pharmaceuticals Corp. dataQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com
Phio Pharmaceuticals Corp files for offering of up to 11.8 million common shares by the Selling StockholdersSEC filing - MarketScreener
[S-3] Phio Pharmaceuticals Corp. Shelf Registration Statement | PHIO SEC FilingForm S-3 - Stock Titan
How Phio Pharmaceuticals Corp. (44R1) stock trades under stagflationMarket Activity Recap & AI Optimized Trade Strategies - newser.com
Published on: 2025-11-20 05:56:20 - newser.com
How Phio Pharmaceuticals Corp. stock performs in rate cut cyclesPortfolio Value Summary & Real-Time Stock Entry Alerts - newser.com
Is Phio Pharmaceuticals Corp. (44R1) stock protected from inflationJuly 2025 Analyst Calls & Low Risk Investment Opportunities - newser.com
How Phio Pharmaceuticals Corp. (44R1) stock trades in high volatilityEarnings Summary Report & Accurate Entry/Exit Alerts - newser.com
Published on: 2025-11-19 20:52:55 - newser.com
Published on: 2025-11-19 18:13:16 - newser.com
Published on: 2025-11-19 16:59:54 - newser.com
Published on: 2025-11-19 16:50:52 - newser.com
How Phio Pharmaceuticals Corp. (44R1) stock correlates with oil marketsDay Trade & Free Risk Controlled Daily Trade Plans - newser.com
Insider Buying: Robert Bitterman Acquires Additional Shares of P - GuruFocus
Bitterman buys Phio Pharmaceuticals (PHIO) stock worth $6350 By Investing.com - Investing.com Canada
Bitterman buys Phio Pharmaceuticals (PHIO) stock worth $6350 - Investing.com India
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phio Pharmaceuticals Corp Stock (PHIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 10 '25 |
Buy |
2.42 |
2,000 |
4,840 |
27,149 |
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 21 '25 |
Buy |
1.77 |
3,000 |
5,310 |
22,449 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):